Iloperidone vs Aripiprazole — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Atypical Antipsychotic

Iloperidone

Brand: FANAPT

First FDA approval: 2015-09-15

Atypical Antipsychotic

Aripiprazole

Brand: ABILIFY

First FDA approval: 2002-11-15

Lowest NADACAcquisition cost floor across all NDCs

$30.46Per unit

$0.098Per unit

Average NADACAcross all dosage forms and strengths

$41.04Up to $60.25

$62.47Up to $2859.97

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

22108 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$132.9MFull year

$1.45BFull year

Part D claims (CY24)Total fills, all strengths

65K8K beneficiaries

6.2M1.3M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$2,051Per claim, all NDCs

$233Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1592Substantial friction

1127Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

984Limited friction

372Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes22 manufacturers